Paris (ots/PRNewswire) - - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was ...
Paris (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets). The CHMP has recommended the ...
Paris (ots/PRNewswire) - - SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational ...
Paris (ots/PRNewswire) - - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) ...
Paris and Brisbane, California (ots/PRNewswire) - - Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial ...
Lyon, France (ots/PRNewswire) - - Global Clinical Study Program Across Dengue Endemic Regions in Latin America and Asia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that its investigational tetravalent dengue vaccine is entering into a pediatric clinical study in Thailand to assess the ...
Lyon, France (ots/PRNewswire) - - Novel Vaccine Approach Tested in the UK Against One of the Most Common Causes of Hospital-Acquired Infection in Europe and North America Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN et NYSE : SNY), announced today that it is sponsoring a phase II clinical study of a vaccine against ...
Paris (ots/PRNewswire) - - Multaq(R) (dronedarone) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the ...
Paris, November 12 (ots/PRNewswire) - - Sanofi Pasteur and Chumakov Institute Russian Academy Medical Sciences Providers of Inactivated Polio Vaccine (IPV) IMOVAX PolioTM for Russia National "Project Health" Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that Russia has ...
New Orleans, November 11 (ots/PRNewswire) - - Baseline Data from RecordAF Presented at American Heart Association's Scientific Sessions Today Baseline data from the REgistry on Cardiac rhythm disORDers - an international, observational, prospective survey assessing the control of Atrial Fibrillation ...
New Orleans, Louisiana, November 11 (ots/PRNewswire) - - New Post-Hoc Analysis From Athena Study Showed That Multaq(R) on Top of Standard Therapy Significantly Decreased the Total Number of Hospital Days by 28% in Patients With Atrial Fibrillation or Flutter NEW ORLEANS, Louisiana, November 11 /PRNewswire/ ...
Paris (ots/PRNewswire) - - Sanofi-aventis Will Comply With the European Authorities Request to Temporarily Suspend the Marketing Authorisation of Acomplia(R) in Obese and Overweight Patients and Will Make Every Effort to Actively Support Patients and Health Care Professionals in This Process. - ...
Paris (ots/PRNewswire) - - Abstracts 186 and 1003 Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin regimen with LANTUS(R) (insulin ...
Paris (ots/PRNewswire) - - Abstracts 185 and 1112 Sanofi-aventis, a world leader in diabetes care, announced results from two randomized clinical studies presented at the European Association for the Study of Diabetes (EASD) 44th Annual Meeting demonstrating that the "basal plus" insulin strategy ...
Paris (ots/PRNewswire) - - The THIN, ROLE and LIVE-DE Studies Used Medical Databases or Medical Records to Compare the Benefits of Different Insulin Treatments in Thousands of People Living With Type 2 Diabetes - Abstracts 1000, 1001 and 1004 Sanofi-aventis, a world leader in diabetes care, announced ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization (WHO) over 3 years for the establishment of an H5N1 vaccine global stockpile. ...
Buenos Aires, Argentina (ots/PRNewswire) - Today at the World Congress of Cardiology (WCC), the press conference entitled "New Perspectives in Atrial Fibrillation Management" chaired by John Camm, Professor of Clinical Cardiology, St George's University of London, highlighted the importance of the newly announced ...
Paris (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular ...
Lyon, France (ots/PRNewswire) - - Six Million Doses of Stamaril(TM) Vaccine Shipped in Record Time to Brazil and Paraguay Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, announced today that six million doses of Stamaril(TM)(1) yellow fever vaccine have been shipped upon UNICEF's request to respond to the yellow fever epidemic in Latin ...
Lyon, France (ots/PRNewswire) - - Scientific Advances in Vaccine Research may Lead to Improved Vaccine Against Leading Cause of Death in Developing Countries Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has signed a collaborative research and license agreement with the Statens Serum Institut of Denmark (SSI) for ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that the anticoagulant Clexane(R) (enoxaparin sodium injection) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the prevention of venous thromboembolism (VTE) in patients undergoing orthopaedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery. Venous ...
Lyon, France (ots/PRNewswire) - - Exclusive Agreement for Rabies Monoclonal Antibodies to Fight Fatal Disease Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. (Euronext, NASDAQ: CRXL) for Crucell's rabies monoclonal antibodies ...
Lyon, France, November 6 (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today positive results in the development of a vaccine for the global prevention of dengue fever, one of the most widespread tropical diseases. The results are being presented today at the American Society of Tropical Medicine and Hygiene (ASTMH)'s ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for a Supplemental New Drug Application (sNDA) for the indication of "Acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for which ...
Paris (ots/PRNewswire) - Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction (STEMI) for Lovenox(R) vs Unfractionnated Heparin (UFH). The ExTRACT-TIMI ...
Paris, France (ots/PRNewswire) - - EXCLAIM is the First International Study to Show That Extended Thromboprophylaxis Reduces VTE Risk in Acutely-ill Medical Patients With a Statistically Significant 44% Sanofi-aventis announced today the results of the EXCLAIM (EXtended CLinical prophylaxis in Acutely ...
Paris (ots/PRNewswire) - - Lovenox(R) is the Low-Molecular Weight Heparin, Approved in the United States for the Broadest Range of Indications Sanofi-aventis announced today that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the anticoagulant Lovenox(R) ...
Lyon, France (ots/PRNewswire) - - New Vaccine Will Help Improve Public Health in Japanese Encephalitis Endemic Countries Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today it has entered into an agreement with Acambis plc to license a single dose vaccine against Japanese encephalitis (JE), ChimeriVaxTM-JE, to help improve ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Record Production Capabilities Strengthen sanofi pasteur's Global Leadership in the Fight Against Seasonal Influenza and Place the Company at the Forefront of Pandemic Readiness sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY; EURONEXT: SAN), announced that it ...
Orlando, Florida (ots/PRNewswire) - - The PREVAIL Study Showed That in Acute Ischemic Stroke Patients Treated With Clexane(R) / Lovenox(R), the Risk of Having a VTE was Lowered by a Significant 43% With no Significant Increase in Clinically Important Bleedings When Compared to UFH Sanofi-aventis announced ...